Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 15/20 | 0.47 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25478136 | 0.91 | BTK (0.46) | BTKTNK2PARP10LTA4H | |
| SCHEMBL22243254 | 0.89 | BTK (0.46) | BTKTNK2KCNH2EGFR | |
| SCHEMBL24041268 | 0.89 | BTK (0.58) | BTKKCNH2EGFR | |
| SCHEMBL24041280 | 0.89 | BTK (0.43) | BTKTNK2KCNH2EGFR | |
| SCHEMBL22243291 | 0.88 | BTK (0.42) | BTKTNK2KCNH2 | |
| SCHEMBL25478813 | 0.87 | BTK (0.49) | BTKTNK2PARP10LTA4HEGFR | |
| SCHEMBL22243243 | 0.85 | BTK (0.51) | BTKTNK2KCNH2EGFR | |
| SCHEMBL24192694 | 0.84 | BTK (0.47) | BTKTNK2PARP10LTA4H | |
| SCHEMBL22243292 | 0.83 | BTK (0.45) | BTKEGFR | |
| SCHEMBL25474330 | 0.83 | BTK (0.53) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3912980-A1 | CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITOR | Minghui Pharmaceutical (Shanghai) Limited (CN) | 2021-11-24 | — | — | EP | disclosed |
| WO-2020147798-A1 | CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITOR | 明慧医药（上海）有限公司 | 2020-07-23 | — | — | WO | disclosed |